FDA’s Banner Year for Drug Approvals: Time to Change the Focus
This article was originally published in RPM Report
Executive Summary
FDA is entering a big legislative year with a good story to tell based on 30 new molecular entity approvals. But the level of submissions remains constant—suggesting it may be time to shift the focus from what comes out of FDA to what makes it in.
You may also be interested in...
FDA’s Very Big Year: Drug Approvals Approach Record Levels
In 2012, FDA new drug approvals reached levels not seen since the peak years of the 1990s. FDA counts 39 NMEs; The RPM Report tracks a different metric—ICTs—and FDA topped 30 for the first time since 1999. The approval spike clearly reflects a regulatory agency operating at peak efficiency. Is there also (at last) a true bulge in innovative products making it through development?
What's "New" at FDA?
Amarin, biosimilars and why FDA’s low point was even lower than you thought.
What’s Going On With Eliquis and Xarelto at FDA?
A key date was removed from FDA’s tentative advisory committee calendar. But a panel is still expected to review BMS’s anti-clotting agent Eliquis and a new indication for J&J’s Xarelto in ACS.